Switzerland-based generic and biosimilar drug maker Sandoz (SWX: SDZ) officially became a fully independent company last week, completing its separation from Novartis (NYSE: NVS) as previously announced. The decision to spin off Sandoz was first presented in 2022, aimed at establishing a global leader in generics and biosimilars while allowing Novartis to focus more intently on its core operations, thereby maximizing shareholder value.
Trading and Market Impact
Following the spin-off, Sandoz now trades on the SIX Swiss Exchange under the ticker symbol SDZ and has achieved an investment-grade credit rating. This transition marks a significant milestone for the company as it embarks on its journey as an independent entity.
Global Reach and Economic Impact
According to Sandoz CEO Richard Saynor, the company reaches approximately 500 million patients across more than 100 countries. Its bioequivalent products are estimated to generate over USD 17 billion in annual savings in Europe and the US markets alone, underscoring the firm’s impact on healthcare affordability and access.-Fineline Info & Tech
